1. Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.
- Author
-
Mouri, Atsuto, Watanabe, Satoshi, Tokito, Takaaki, Nagai, Yoshiaki, Saida, Yu, Imai, Hisao, Yamaguchi, Ou, Kobayashi, Kunihiko, Kaira, Kyoichi, and Kagamu, Hiroshi
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *COMBINATION drug therapy , *ANTINEOPLASTIC agents , *QUESTIONNAIRES , *CHEMORADIOTHERAPY , *CANCER patients , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *MULTIVARIATE analysis , *EVALUATION of medical care , *DRUG efficacy , *MEDICAL records , *ACQUISITION of data , *NIVOLUMAB , *LUNG cancer , *DISEASE relapse , *CONFIDENCE intervals , *COMPARATIVE studies , *IPILIMUMAB , *EVALUATION - Abstract
Simple Summary: The clinical significance of nivolumab plus ipilimumab in patients with recurrence after chemoradiotherapy followed by durvalumab remains unclear. We investigated the efficacy and safety of nivolumab plus ipilimumab in patients who relapsed after chemoradiotherapy followed by durvalumab. The 6- and 12-month PFS rates for nivolumab plus ipilimumab for relapse after durvalumab were 46.7% and 36.4%, indicating a long-tail plateau. Nivolumab plus ipilimumab was particularly effective in patients treated with durvalumab for 6 months or more. Therefore, nivolumab plus ipilimumab is a promising treatment option for patients who have relapsed after CCRT–durvalumab, with good tolerability. Nivolumab plus ipilimumab showed promising efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). The efficacy of the nivolumab plus ipilimumab combination regimen in NSCLC patients who relapse after durvalumab consolidation following concurrent chemoradiotherapy (CCRT) has not been determined. Between January 2021 and June 2022, clinical data were retrospectively extracted from the medical records of patients with NSCLC who received nivolumab plus ipilimumab after CCRT and durvalumab consolidation. A total of 30 patients were included in this analysis. The median number of durvalumab treatment cycles was 11. Median PFS and OS with nivolumab plus ipilimumab were 4.2 months (95% confidence interval [CI]: 0.7–7.7) and 18.5 months (95% CI: 3.5–33.5), respectively. The 6-month and 12-month PFS rates were 46.7% (95% CI: 28.8–64.5) and 36.4% (95% CI: 19.0–53.7). In multivariate analysis, a significant correlation was observed between a durvalumab treatment duration of 6 months or more and PFS (p = 0.04) as well as OS (p = 0.001). Grade 3 adverse events, including pneumonitis, dermatitis, and colitis, occurred in 10% of the patients. This study suggests that nivolumab plus ipilimumab is effective, especially in patients who have received durvalumab for 6 months or more, and tolerable for patients who relapsed after durvalumab following CCRT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF